Dr Reddy’s Laboratories vs Cipla: Which Stock Should You Track
- July 31, 2026
- Posted by: Ankit Jaiswal
- Category: News
Dr Reddy’s Laboratories vs Cipla: a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint vs a leading Indian pharmaceutical company with respiratory ca…
Dr Reddy’s Laboratories vs Cipla is a comparison investors search for because the two companies represent genuinely different positions within Pharmaceuticals. This Dr Reddy’s Laboratories vs Cipla breakdown goes beyond generic labels and looks at real numbers: reach, products, the latest results each company has declared, and how each stock is positioned today. Understanding Dr Reddy’s Laboratories vs Cipla this way is more useful than a surface-level label, because it shows where each company actually stands rather than how it describes itself.
Dr Reddy’s Laboratories vs Cipla: Reach and Market Position
In the Dr Reddy’s Laboratories vs Cipla comparison, Dr Reddy’s Laboratories stands out for a Hyderabad-based global pharmaceutical major with a diversified footprint across North America, Europe, Emerging Markets and India. This scale gives Dr Reddy’s Laboratories a distinct position within Pharmaceuticals that shapes how it competes.
Click Here – Get Free Investment Predictions
Cipla, on the other hand, is built around a leading Indian pharmaceutical company with a strong respiratory and India-business franchise, maintaining a net cash position of over Rs 9,000 crore. Comparing Dr Reddy’s Laboratories vs Cipla on reach alone shows two different growth strategies, not a single verdict.
Dr Reddy’s Laboratories vs Cipla: Key Products and Business Mix
Dr Reddy’s Laboratories’s business runs on generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations. This product mix is central to any Dr Reddy’s Laboratories vs Cipla comparison, since it explains where each company’s revenue actually comes from.
Cipla instead leans on respiratory therapies, generic drugs, oncology treatments, and One India branded formulations. The Dr Reddy’s Laboratories vs Cipla product comparison shows these are genuinely different businesses, not just different brand names in the same category.
Dr Reddy’s Laboratories vs Cipla: Latest Results
Looking at real numbers rather than claims, Dr Reddy’s Laboratories’s latest disclosed results show Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American generic sales faced pricing pressure on key molecules including lenalidomide; Emerging Markets revenue grew 31% YoY and India grew 17% YoY. This is the clearest evidence available for the Dr Reddy’s Laboratories vs Cipla comparison on Dr Reddy’s Laboratories’s side.
Cipla’s latest disclosed results show Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contraction and new labour-code-related costs even as India business revenue hit a record Rs 3,452 crore; FY26 revenue was a record Rs 28,000 crore. Weighing Dr Reddy’s Laboratories vs Cipla on actual results, rather than headline positioning, is what separates a useful comparison from a generic one.
Compare Dr Reddy’s Laboratories and Cipla Fundamentals on the Univest Screener
Dr Reddy’s Laboratories vs Cipla: Stock and Valuation
On the market side, Dr Reddy’s Laboratories is described as: Shares touched a 52-week low following the Q1 FY27 results per market reports. Cipla is described as: Maintained a strong net cash position despite the profit decline. The Dr Reddy’s Laboratories vs Cipla valuation gap often reflects how the market is pricing each company’s growth and risk profile differently.
Dr Reddy’s Laboratories vs Cipla: Quick Comparison Table
| Parameter | Dr Reddy’s Laboratories | Cipla |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market position | a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint | a leading Indian pharmaceutical company with respiratory category leadership |
| Reach | a Hyderabad-based global pharmaceutical major with a diversified footprint across North Am | a leading Indian pharmaceutical company with a strong respiratory and India-business franc |
| Latest results | Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs | Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, wi |
Conclusion
Dr Reddy’s Laboratories vs Cipla ultimately comes down to two companies solving similar problems in different ways. Dr Reddy’s Laboratories brings a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Cipla brings a leading Indian pharmaceutical company with respiratory category leadership. Investors weighing Dr Reddy’s Laboratories vs Cipla should track both companies’ upcoming results and valuation gap rather than picking a side on reputation alone. This Dr Reddy’s Laboratories vs Cipla breakdown is a starting point, not a final verdict.
Download the Univest iOS App or Univest Android App to track Dr Reddy’s Laboratories and Cipla live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the main difference between Dr Reddy’s Laboratories and Cipla?
Ans. The main difference in the Dr Reddy’s Laboratories vs Cipla comparison lies in scale and business mix. Dr Reddy’s Laboratories is built on a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Cipla is positioned around a leading Indian pharmaceutical company with respiratory category leadership.
How do Dr Reddy’s Laboratories and Cipla’s latest results compare?
Ans. Comparing Dr Reddy’s Laboratories vs Cipla on latest disclosed results: Dr Reddy’s Laboratories reported Q1 FY27 consolidated net profit of around Rs 1,290 crore, down about 8% YoY, on revenue of about Rs 7,650-8,071 crore, as North American gen, while Cipla reported Q1 FY27 net profit of Rs 785.55 crore, down 39.2% YoY, on revenue of Rs 7,119.28 crore, up 2.33%, with the decline driven by margin contract.
What sector do Dr Reddy’s Laboratories and Cipla operate in?
Ans. Dr Reddy’s Laboratories operates in Pharmaceuticals and Cipla operates in Pharmaceuticals. Even where the sectors overlap, the Dr Reddy’s Laboratories vs Cipla comparison shows different product mixes and market positions.
Should I invest in Dr Reddy’s Laboratories or Cipla?
Ans. Both Dr Reddy’s Laboratories and Cipla have distinct strengths within their space. Investors comparing Dr Reddy’s Laboratories vs Cipla should review the latest quarterly results, valuation and their own risk profile, and consult a financial advisor before deciding.
What are the key products of Dr Reddy’s Laboratories?
Ans. Dr Reddy’s Laboratories’s key products and business lines include generic drugs, biosimilars, active pharmaceutical ingredients, and branded formulations.
What are the key products of Cipla?
Ans. Cipla’s key products and business lines include respiratory therapies, generic drugs, oncology treatments, and One India branded formulations.
How do Dr Reddy’s Laboratories and Cipla compare on market position?
Ans. On market position, Dr Reddy’s Laboratories holds a leading Indian pharmaceutical company with a diversified global generics and biosimilars footprint, while Cipla holds a leading Indian pharmaceutical company with respiratory category leadership. The Dr Reddy’s Laboratories vs Cipla comparison shows both companies lead in different ways rather than one being universally ahead.
